Seeking Alpha

Biogen's (BIIB) longer-lasting multiple sclerosis drug peginterferon beta-1a meets the goals of...

Biogen's (BIIB) longer-lasting multiple sclerosis drug peginterferon beta-1a meets the goals of a Phase III trial, helping to cut patients' risk of relapse by 36% when injected every two weeks, and by 28% when given every four weeks. Peginterferon is a version of Biogen's blockbuster Avonex medicine, which is taken once a week. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|